

November 15, 2015 • Volume 21 • Number 22

Highlights of This Issue 4987

SPECIAL FEATURES

CCR 20th Anniversary Commentary

- 4989** CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology
Axel Hoos, Jedd D. Wolchok, Rachel W. Humphrey, and F. Stephen Hodi

- 4992** CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer
Niven Mehra, Zafeiris Zafeiriou, David Lorente, Leon W.M.M. Terstappen, and Johann S. de Bono

CCR Translations

- 4996** Metabolic Imaging as a Biomarker of Early Radiation Response in Tumors
Stephen Y. Lai, C. David Fuller, Pratip K. Bhattacharya, and Steven J. Frank
See related article, p. 5073

- 4999** "Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer
Angela DeMichele and Lewis A. Chodosh
See related article, p. 5121


Molecular Pathways

- 5002** Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor
Ana Sebio and Heinz-Josef Lenz
- 5008** Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer
Benjamin Purov

CCR Focus

- 5014** How Do Cancer Cells Die?
Susan E. Bates

- 5015** Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!
Anthony Letai

- 5021** BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
 Christopher J. Gibson and Matthew S. Davids

- 5030** Promises and Challenges of Smac Mimetics as Cancer Therapeutics
Simone Fulda

- 5037** Autophagy, Metabolism, and Cancer
Eileen White, Janice M. Mehnert, and Chang S. Chan

- 5047** How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Luis Martínez-Lostao, Alberto Anel, and Julián Pardo

Review

- 5057** Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Lesley Seymour, Susan Groshen, Gary L. Rosner, Daniel M. Sullivan, David R. Spriggs, Steven Reeves, Amy Gravell, S. Percy Ivy, and Mark J. Ratain

CANCER THERAPY: CLINICAL

- 5064** A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Yuna Guo, S. Ray Kenney, Linda Cook, Sarah F. Adams, Teresa Rutledge, Elsa Romero, Tudor I. Oprea, Larry A. Sklar, Edward Bedrick, Charles L. Wiggins, Huining Kang, Lesley Lomo, Carolyn Y. Muller, Angela Wandinger-Ness, and Laurie G. Hudson

PERSONALIZED MEDICINE AND IMAGING

- 5073** ¹³C-MR Spectroscopic Imaging with Hyperpolarized [1-¹³C]pyruvate Detects Early Response to Radiotherapy in SCC Tumors and HT-29 Tumors
Keita Saito, Shingo Matsumoto, Yoichi Takakusagi, Masayuki Matsuo, H. Douglas Morris, Martin J. Lizak, Jeeva P. Munasinghe, Nallathamby Devasahayam, Sankaran Subramanian, James B. Mitchell, and Murali C. Krishna
See related commentary, p. 4996



Table of Contents

5082 Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Bryan P. Schneider, Lang Li, Milan Radovich, Fei Shen, Kathy D. Miller, David A. Flockhart, Guanglong Jiang, Gail Vance, Laura Gardner, Matteo Vatta, Shaochun Bai, Dongbing Lai, Daniel Koller, Fengmin Zhao, Anne O'Neill, Mary Lou Smith, Elda Railey, Carol White, Ann Partridge, Joseph Sparano, Nancy E. Davidson, Tatiana Foroud, and George W. Sledge, Jr

5092 Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Peter H. O'Donnell, Sanja Karovic, Theodore G. Karrison, Linda Janisch, Matthew R. Levine, Pamela J. Harris, Blase N. Polite, Ezra E.W. Cohen, Gini F. Fleming, Mark J. Ratain, and Michael L. Maitland

5131 Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)

Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien-Hsing Chang, and David M. Goldenberg

5139 Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers

Kedan Lin, Bonnee Rubinfeld, Crystal Zhang, Ron Firestein, Eric Harstad, Leslie Roth, Siao Ping Tsai, Melissa Schutten, Keyang Xu, Maria Hristopoulos, and Paul Polakis

5151 Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer



Anand Kamal Singh, Nishi Chandra, and Sharmila A. Bapat

CANCER THERAPY: PRECLINICAL

5100 Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

M. Emmy M. Dolman, Evon Poon, Marli E. Ebus, Ilona J.M. den Hartog, Carel J.M. van Noesel, Yann Jamin, Albert Hallsworth, Simon P. Robinson, Kevin Petrie, Rolf W. Sparidans, Robbert J. Kok, Rogier Versteeg, Huib N. Caron, Louis Chesler, and Jan J. Molenaar

5110 Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer

Viviana De Rosa, Francesca Iommelli, Marcello Monti, Rosa Fonti, Giuseppina Votta, Maria Patrizia Stoppelli, and Silvana Del Vecchio

5121 Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer

Suzanne E. Wardell, Matthew J. Ellis, Holly M. Alley, Koleen Eisele, Todd VanArsdale, Stephen G. Dann, Kim T. Arndt, Tina Primeau, Elizabeth Griffin, Jieya Shao, Robert Crowder, Jin-Ping Lai, John D. Norris, Donald P. McDonnell, and Shunqiang Li
See related commentary, p. 4999

BIOLOGY OF HUMAN TUMORS

5164 Cellular Senescence Markers p16^{INK4a} and p21^{CIP1/WAF1} Are Predictors of Hodgkin Lymphoma Outcome

Anna Calì, Alberto Zamò, Maurilio Ponzoni, Maria Elisabetta Zanolin, Andrés J.M. Ferreri, Serena Pedron, Licia Montagna, Claudia Parolini, Vadim E. Fraifeld, Marina Wolfson, Hagai Yanai, Giovanni Pizzolo, Claudio Doglioni, Fabrizio Vinante, and Marco Chilosi

5173 TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer

Rongrong Wei, Lan Cao, Hengying Pu, Hongwei Wang, Yonglan Zheng, Xiaomin Niu, Xiaoling Weng, Hong Zhang, Murray J. Favus, Lanjun Zhang, Weihua Jia, Yixin Zeng, Christopher I. Amos, Shun Lu, Hui-Yun Wang, Yun Liu, and Wanqing Liu

CORRECTION

5181 Correction: Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

 AC icon indicates Author Choice


 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows ESR1 expression in MCF7 breast cancer cells as detected by in-cell Western blot analysis. Diminishing signal (left to right) denotes loss of ESR1 expression in response to treatment with selective estrogen receptor downregulators. For details, see the article by Wardell and colleagues on page 5121 of this issue.



Clinical Cancer Research

21 (22)

Clin Cancer Res 2015;21:4987-5181.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/22>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/22>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.